Zenvia: Phase III started

AVNR began the double-blind, international Phase III STAR trial in 270 patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS) to compare 2 doses of Zenvia (20 mg or 30 mg dextrom...